Recurrent fever after a holiday in Turkey

BMJ (Online)

Volumn 344, Issue 7839, 2012, Pages

  Egli, Adrian ^a   Khanna, Nina ^a   Schmid, Thomas ^a   Rudin, Sonja ^a   Frei, Reno ^a   Blaich, Annette ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; CALCIUM CHANNEL BLOCKING AGENT; GAMMA GLUTAMYLTRANSFERASE; ANTIINFECTIVE AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAMNESIS; ANGIOCARDIOGRAPHY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BARE METAL STENT; BRUCELLOSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; ECHOGRAPHY; FATTY LIVER; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERTENSION; LEISURE; MALE; NIGHT SWEAT; PRIORITY JOURNAL; RECURRENT FEVER; SPLENOMEGALY; SWITZERLAND; THORAX PAIN; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; TURKEY (REPUBLIC); BRUCELLA; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; RISK FACTOR; STENT; TRAVEL; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BRUCELLA; BRUCELLOSIS; FEVER; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; STENTS; TRAVEL; TREATMENT OUTCOME; TURKEY;

EID: 84859002180     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d7832     Document Type: Article

References (12)

1. Baysallar M, Aydogan H, Kilic A, Kucukkaraaslan A, Senses Z, Doganci L. Evaluation of the BacT/ALERT and BACTEC 9240 automated blood culture systems for growth time of Brucella species in a Turkish tertiary hospital. Med Sci Monit 2006;12:BR235-38. (Pubitemid 44042831)
2. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med 2005;352:2325-36.
3. Centers for Disease Control and Prevention. Brucellosis. 2007. www.cdc.gov/ncidod/dbmd/diseaseinfo/Brucellosis-g.htm.
4. Franco MP, Mulder M, Gilman RH, Smits HL. Human brucellosis. Lancet Infect Dis 2007;7:775-86. (Pubitemid 350152041)
5. Buzgan T, Karahocagil MK, Irmak H, Baran AI, Karsen H, Evirgen O, et al. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. Int J Infect Dis 2010;14:e469-78.
6. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis 2006;6:91-9. (Pubitemid 43138907)
7. Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 7th ed. Churchill Livingstone, 2010:2921-5.
8. Roop RM II, Gaines JM, Anderson ES, Caswell CC, Martin DW. Survival of the fittest: how Brucella strains adapt to their intracellular niche in the host. Med Microbiol Immunol 2009;198:221-38.
9. Sabundayo BP, Standiford HC. Tetracyclines and analogues. In: Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, eds. Antimicrobial therapy and vaccines. Vol II: antimicrobial agents. 2nd ed. ESun Technologies, 2005:461-76.
10. Peloquin CA, Vernon AA. Rifamycins for mycobacterial infections. In: Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, eds. Antimicrobial therapy and vaccines. Vol II: antimicrobial agents. 2nd ed. ESun Technologies, 2005:383-401.
11. Lecároz C, Blanco-Prieto MJ, Burrell MA, Gamazo C. Intracellular killing of Brucella melitensis in human macrophages with microsphere- encapsulated gentamicin. J Antimicrob Chemother 2006;58:549-56. (Pubitemid 44288118)
12. Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med 2007;4:1872-78.